NCT06083103

Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)

Contribution of PET/MRI in Locally Advanced Cervical Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Centre Paul Strauss · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

\[18 F\]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is particularly promising. Its usefulness seems obvious in certain tumor types, but its place in the staging of cervical cancers has never been explored in a prospective trial to our knowledge. Previously, a comparative retrospective study from 2009 found a better sensitivity of PET fused to diagnostic MRI images compared to PET/CT (positron emission tomography/computed tomography) in the detection of metastatic lymph nodes (54 and 44% respectively). It was an a posteriori fusion of images, from images acquired by PET-CT.

Detailed description

This monocentric, prospective trial aims at comparing performances of 18F-FDG PET/MRI versus standard PET/CT in the detection of lymph node metastases in cervical cancer patients. Specificity and sensitivity of both exams will be compared at one timepoint, during the PET/CT prescribed in routine care for assessment of extension. PET/MRI will be conducted directly after PET/CT and a unique dose of 18F-FDG radiotracer will be used for both exams.

Conditions

• Cervical Cancer

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	18-FDG PET-MRI	For this trial, 18-FDG PET-MRI will be conducted directly after PET-CT using a single dose of radiotracer

Timeline

• Start date: 2023-10-12
• Primary completion: 2026-09-11
• Completion: 2026-09-11
• First posted: 2023-10-13
• Last updated: 2026-02-02

Locations

1 site across 1 country: France